We serve Chemical Name:1-(2-hydroxy-4,6-dimethoxyphenyl)-2-phenylethanone CAS:39604-66-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-(2-hydroxy-4,6-dimethoxyphenyl)-2-phenylethanone
CAS.NO:39604-66-5
Synonyms:2-hydroxy-4,6-dimethoxyphenyl benzyl ketone;4,6-dimethoxy-2-hydroxyphenyl benzyl ketone;2-hydroxy-4,6-dimethoxy-deoxybenzoin;MFCD00218596;2-Hydroxy-4,6-dimethoxy-desoxybenzoin;2′-hydroxy-4′,6-dimethoxy-2-phenylacetophenone;benzyl 2-hydroxy-4,6-dimethoxyphenyl ketone
Molecular Formula:C16H16O4
Molecular Weight:272.29600
HS Code:2914509090
Physical and Chemical Properties:
Melting point:114-118ºC(lit.)
Boiling point:461.4ºC at 760 mmHg
Density:1.193g/cm3
Index of Refraction:1.58
PSA:55.76000
Exact Mass:272.10500
LogP:2.83480
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3077 9/PG 3
Packing Group:
Contact us for information like 2-hydroxy-4,6-dimethoxyphenyl benzyl ketone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,benzyl 2-hydroxy-4,6-dimethoxyphenyl ketone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Hydroxy-4,6-dimethoxy-desoxybenzoin Use and application,benzyl 2-hydroxy-4,6-dimethoxyphenyl ketone technical grade,usp/ep/jp grade.
Related News: Grégoire Boutonnet, Chief Operating Officer of NOVA, said: “I am thrilled to be joining the NOVA team at this exciting period of growth as we launch the Jinkō platform towards wider adoption in the clinical trial development space. 1-(5-Methyl-indan-4-yl)-ethanol manufacturers With no new systemic lupus erythematosus treatments in over a decade, we’re working to make this new medicine available as soon as possible.” N-[3-(2,4-Dioxo-3,4,7,8-tetrahydro-2H-thiopyran[4,3-d]pyrimidin-1(5H)-yl)propyl]-N-methyl-2,1,3-benzothiadiazole-4-sulphonamide suppliers It’s official. Nearly two years after the FDA granted conditional approval to Merck’s Keytruda and Eisai’s Lenvima for endometrial cancer, the U.S. regulator has blessed the combination therapy, with no strings attached. (3S,10R,13S,17R)-17-(3,3-dimethoxypropyl)-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol vendor & factory.
